A Glimpse Into The Expert Outlook On Protagonist Therapeutics Through 8 Analysts
Benzinga Insights 8 months ago
Analyst Ratings
Analysts' ratings for Protagonist Therapeutics (NASDAQ:PTGX) over the last quarter vary from bullish to bearish, as provided by 8 analysts.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 3 | 0 | 0 | 0 |
| Last 30D | 1 | 2 | 0 | 0 | 0 |
| 1M Ago | 2 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 1 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $111.62, along with a high estimate of $118.00 and a low estimate of $100.00. This current average reflects an increase of 19.23% from the previous average price target of $93.62.
Investigating Analyst Ratings: An Elaborate Study
The analysis of recent analyst actions sheds light on the perception of Protagonist Therapeutics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Tara Bancroft | TD Cowen | Raises | Buy | $100.00 | $90.00 |
| Etzer Darout | Barclays | Raises | Overweight | $113.00 | $108.00 |
| Jonathan Wolleben | Citizens | Raises | Market Outperform | $112.00 | $102.00 |
| Roger Song | Jefferies | Raises | Buy | $118.00 | $95.00 |
| Douglas Tsao | HC Wainwright & Co. | Raises | Buy | $117.00 | $80.00 |
| Srikripa Devarakonda | Truist Securities | Raises | Buy | $110.00 | $88.00 |
| Etzer Darout | Barclays | Raises | Overweight | $108.00 | $88.00 |
| Geoff Meacham | Citigroup | Raises | Buy | $115.00 | $98.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Protagonist Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Protagonist Therapeutics compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for Protagonist Therapeutics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Protagonist Therapeutics's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Protagonist Therapeutics analyst ratings.
Delving into Protagonist Therapeutics's Background
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
Protagonist Therapeutics: Financial Performance Dissected
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Protagonist Therapeutics displayed positive results in 3M. As of 30 September, 2025, the company achieved a solid revenue growth rate of approximately 0.79%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -834.87%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Protagonist Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -5.99%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Protagonist Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -5.54%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Protagonist Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of 0.02, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Analyst Ratings: What Are They?
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.